A status update of modified oligonucleotides for chemotherapeutics applications

Current Protocols in Nucleic Acid Chemistry

Volumn , Issue SUPPL.46, 2011, Pages

  Sanghvi, Yogesh S ^a  

^a RASAYAN INC   (United States)

Author keywords

Antisense; Aptamers; MicroRNA; Oligonucleotides; RNAi; ShRNA; SiRNA

Indexed keywords

AEG 35156; AGANIRSEN; ALICAFORSEN; ALN RSV 01; ANTISENSE OLIGONUCLEOTIDE; APTAMER; CPG OLIGODEOXYNUCLEOTIDE; CUSTIRSEN; DEFIBROTIDE; ENDOTOXIN; ETEPLIRSEN; FOMIVIRSEN; GATAPARSEN; HEAVY METAL; HEPATITIS B VACCINE; IMETELSTAT; IMMUNOSTIMULATING AGENT; ISIS 113715; LOCKED NUCLEIC ACID; MICRORNA; MIPOMERSEN; MORPHOLINO OLIGONUCLEOTIDE; OBLIMERSEN; PEGAPTANIB; PHOSPHORAMIDOUS ACID; PYRROCAINE; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; TRABEDERSEN; UNINDEXED DRUG;

ANTISENSE THERAPY; ARTICLE; CHEMICAL MODIFICATION; CHEMOTHERAPY; CROSS COUPLING REACTION; DESALINATION; DRUG INDICATION; DRUG PURIFICATION; DRUG SYNTHESIS; FREEZE DRYING; GENE SILENCING; HUMAN; IMMUNOSTIMULATION; ION EXCHANGE CHROMATOGRAPHY; MOLECULAR WEIGHT; OLIGONUCLEOTIDE THERAPY; OXIDATION; PH; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN MODIFICATION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; UNITED STATES; WATER CONTENT;

EID: 84856402483     PISSN: 19349270     EISSN: 19349289     Source Type: Journal    
DOI: 10.1002/0471142700.nc0401s46     Document Type: Article

References (38)

1. Allerson, C.R., Sioufi, N., Jarres, R., Prakash, T.P., Naik, N., Berdeja, A., Wanders, L., Griffey, R.H., Swayze, E.E., and Bhat, B. 2005. Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J. Med. Chem. 48:901-904.
2. Behlke, M.A. 2008. Chemical modification of siRNAs for in vivo use. Oligonucleotides 18:305-320.
3. Bennett, C.F. and Swayze, E.E. 2010. RNA targeting therapeutics: Molecularmechanisms of antisense oligonucleotides as therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50:259-293.
4. Bonilla, J.V. and Srivatsa, G.S. 2011. Handbook of analysis of oligonucleotides and related products. CRC Press, Boca Raton, Fla.
5. Bramsen, J.B., Laursen, M.B., Nielsen, A.F., Hansen, T.B., Bus, C., Langkjaer, N., Babu, B.R., Højland, T., Abramov, M., Van Aerschot, A., Odadzic, D., Smicius, R., Haas, J., Andree, C., Barman, J., Wenska, M., Srivastava, P., Zhou, C., Honcharenko, D., Hess, S., Müller, E., Bobkov, G.V., Mikhailov, S.N., Fava, E., Meyer, T.F., Chattopadhyaya, J., Zerial, M., Engels, J.W., Herdewijn, P., Wengel, J., and Kjems, J. 2009. A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res. 37:2867-2881.
6. Bramsen, J.B., Pakula, M.M., Hansen, T.B., Bus, C., Langkjær, N., Odadzic, D., Smicius, R., Wengel, S.L., Chattopadhyaya, J., Engels, J.W., Herdewijn, P., Wengel, J., and Kjems, J. 2010. A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Res. 38:5761-5773.
7. Capaldi, D.C. and Scozzari, A.N. 2008. Manufacturing and analytical processes for 2'-O-(2-methoxyethyl)-modified oligonucleotides. In Antisense Drug Technology: Principles, Strategies andApplications (S.T.Crooke, ed.) pp. 401-434. CRC Press, Boca Raton, Fla.
8. Capaldi, D.C., Scozzari, A.N., Cole, D.L., and Ravikumar, V.T. 1999. Is it essential to use anhydrous acetonitrile in the manufacture of phosphorothioate oligonucleotides? Org. Process Res. Develop. 3:485-487.
9. Capaldi, D.C., Gaus, H., Krotz, A.H., Arnold, J., Carty, R.L., Moore, M.N., Scozzari, A.N., Lowery, K., Cole, D.L., and Ravikumar, V.T. 2003. Synthesis of high quality antisense drugs. Addition of acrylonitrile to phosphorothioate oligonucleotides: Adduct characterization and avoidance. Org. Process Res. Develop. 7:832-838.
10. Crooke, S.T. (ed.) 2008. Antisense Drug Technology: Principles, Strategies and Applications. CRC Press, Boca Raton, Fla.
11. Deshmukh, R.R., Eriksson, K.O., Moore, P., Cole, D.L., and Sanghvi, Y.S. 2001. A case study: Oligonucleotide purification from gram to hundred gram scale. Nucleosides Nucleotides Nucleic Acids. 20:567-576.
12. Eleuteri, A., Capaldi, D.C., Krotz, A.H., Cole, D.L., and Ravikumar, V.T. 2000. Pyridinium trifluoroacetate/N-methylimidazole as an efficient activator for oligonucleotide synthesis via the phosphoramidite method. Org. Process Res. Develop. 4:182-189.
13. Eulberg, D., Jarosch, F., Vonhoff, S., and Klussmann, S. 2006. Spiegelmers for therapeutic applications - Use of chiral principles in evolutionary selection techniques. In The Aptamer Handbook. (S. Klussmann, ed.) pp. 417-442. Wiley-VCH, Weinheim, Germany.
14. Gaus, H., Olsen, P., Sooy, K.V., Rentel, C., Turney, B., Walker, K.L., McArdle, J.V., and Capaldi, D.C. 2005. Trichloroacetaldehyde modified oligonucleotides. Bioorg. Med. Chem. Lett. 15:4118-4141.
15. Gjerde, D.T., Hoang, L., and Hornby, D. 2009.RNA Purification and Analysis: Sample Preparation, Extraction, Chromatography. Wiley-VCH, Germany.
16. Guzaev, A.P. 2011. Reactivity of 3H-1,2,4-dithiazole-3thiones and 3H-1,2-dithiole-3thiones as sulfurizing agents for oligonucleotide synthesis. Tetrahedron Lett. 52:434-437.
17. Iversen, P.L. 2008. Morpholinos. In Antisense Drug Technology: Principles, Strategies and Applications (S.T. Crooke, ed.) pp. 565-578. CRC Press, Boca Raton, Fla.
18. Ivleva, V.B., Yu, Y-Q., and Gilar, M. 2010. Ultraperformance liquid chromatography/tandem mass spectrometry (UPLC/MS/MS) and UPLC/MS(E) analysis of RNA oligonucleotides. Rapid Commun. Mass Spectrom. 24:2631-2640.
19. Jadhav, S.R. et al. 2010. Efficient large-scale synthesis of L-RNA amidites as building-blocks for spiegelmers. IRT 2010 Lyon, France. PB121.
20. Keefe, A.D., Pai, S., and Ellington, A. 2010. Aptamers as therapeutics. Nat. Rev. Drug Disc. 9:537-550.
21. Krotz, A.H., Carty, R.L., Scozzari, A.N., Cole, D.L., and Ravikumar, V.T. 2000. Large-scale synthesis of antisense oligonucleotides without chlorinated solvents. Org. Process Res.Develop. 4:190-193.
22. Krotz, A.H., McElroy, B., Scozzari, A.N., Cole, D.L., and Ravikumar, V.T. 2003. Controlled detritylation of antisense oligonucleotides. Org. Process Res. Develop. 7:47-52.
23. Krotz, A.H., Gorman, D., Mataruse, P., Foster, C., Godbout, J.D., Coffin, C.C., and Scozzari, A.N. 2004. Phosphorothioate oligonucleotides of low phosphate diester content: Greater than 99.9% sulfurization efficiency with "aged" solutions of phenylacetyl disulfide (PADS). Org. Process Res. Develop. 8:852-858.
24. Lajmi, A.R., Schwartz, L., and Sanghvi, Y.S. 2004. Membrane-based purification of an antisense oligonucleotide. Org. Process Res. Develop. 8:651-657.
25. Obad, S., dos Santos, C.O., Petri, A., Heidenblad, M., Broom, O., Ruse, C., Fu, C., Lindow, M., Stenvang, J., Straarup, E.M., Hansen, H.F., Koch, T., Pappin, D., Hannon, G.J., and Kauppinen, S. 2011. Silencing of microRNA families by seed-targeting tiny LNAs. Nat. Genet. 43:371-378.
26. Pasternak, A. and Wengel, J. 2011. Unlocked nucleic acid - an RNA modification with broad potential. Org. Biomol. Chem. 9:3591-3597.
27. Rentel, C. 2008. Controlling oligonucleotide quality through identification of critical impurities in phosphoramidite, TIDES Conference, Las Vegas, NV.
28. Sanghvi, Y.S. and Schulte, M. 2004. Therapeutic oligonucleotides: The state-of-the-art in purification technologies. Curr. Op. Drug Discov. Dev. 7:765-776.
29. Sanghvi, Y.S., Ravikumar, V.T., Scozzari, A.N., and Cole, D.L. 2001. Applications of green chemistry in the manufacture of oligonucleotide drugs. Pure Appl. Chem. 73:175-180.
30. Swayze, E.E. and Bhat, B. 2008. The medicinal chemistry of oligonucleotides. In Antisense Drug Technology: Principles, Strategies and applications (S.T. Crooke, ed.) pp. 143-172. CRC Press, Boca Raton, Fla.
31. Taj, S., Narayanan, S., Meenakshi, S.S., Sanghvi, Y.S., Ross, B.S., and Ravikumar, V.T. 2008. Process research on the preparation of DMT protected 2'-O-methoxyethylguanosine for oligonucleotide synthesis in therapeutic applications. Nucleosides, Nucleotides and Nucleic Acids. 27:1024-1033.
32. Tram, K., Sanghvi, Y.S., and Yan, H. 2011. Further optimization of detritylation in solidphase oligodeoxyribonucleotide synthesis. Nucleosides Nucleotides Nucleic Acids. 30:12-19.
33. Thiel, K.W. and Giangrande, P.H. 2009. Therapeutic applications of DNA and RNA aptamers. Oligonucleotides 19:209-222.
34. Viazovkina, E., Mangos, M.M., Elzagheid, M.I., and Damha, M.J. 2002. Solidphase synthesis of 2'-deoxy-2'-fluoro-β-Doligoarabinonucleosides (2'F-ANA) and their phosphoramidite derivatives. Curr. Protoc. Nucleic Acid Chem. 10:4.15.1-4.15.22.
35. Wang, E.S., Wu, K., Chin, A.C., Chen-Kiang, S., Pongracz, K., Gryaznov, S., and Moore, M.A. 2004. Telomerase inhibition with an oligonucleotide telomerase template antagonist: In-vitro and in-vivo studies in multiple myeloma and lymphoma. Blood 103:258-266.
36. Wang, Z., Song, Q., and Sanghvi, Y.S. 2005. Dimethylthiarum disulfide: New sulfur transfer reagent in phosphorothioate oligonucleotide synthesis. In Methods in Molecular Biology, Vol 288: Oligonucleotide synthesis: Methods and Applications. (P. Herdewijn, ed.) pp. 51-63. Humana Press, Totowa, N.J.
37. Watts, J.K. and Corey, D.R. 2010. Clinical status of duplexRNA. Bioorg. Med. Chem. Lett. 20:3203-3207.
38. Wei, W. 2011. MicroRNAandCancer:Methods and Protocols, Methods in Molecular Biology, Vol. 676. Springer, New York.